Anti-IL 23 biologics for the treatment of plaque psoriasis

References

• Menter A, Strober BE, Kaplan DH, et al., Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4): 1029–1072.
   PubMed Web of Science ®Google Scholar
• Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. Jama. 2020;323(19):1945–1960.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021 Apr 3 397(10281):1301–1315.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390.
   PubMed Web of Science ®Google Scholar
• Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014 Jul;71(1):141–150.
   PubMed Web of Science ®Google Scholar
• Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020 Jan;821:117–122.
   PubMed Web of Science ®Google Scholar
• Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2004 Oct;51(4):563–569.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009 May;60(5):824–837.
   PubMed Web of Science ®Google Scholar
• Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2010 May;62(5):838–853.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn A, Avery TD, Li J, et al. Emerging therapeutic applications for fumarates. Trends Pharmacol Sci. 2021 Apr;42(4):239–254.
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics. 2021;15:247–253.
   PubMed Web of Science ®Google Scholar
• Enbrel (etanercept) [package insert]. Thousand Oaks CA: Immunex Corporation; 2021.
   Google Scholar
• Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006 Mar 01;54(3, Supplement 2):S101–S111.
   PubMed Web of Science ®Google Scholar
• Remicade (infliximab) [package insert]. Horsham PA: Janssen Biotech, Inc.; 2021.
   Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan;56(1):31.e1–15.
   PubMed Web of Science ®Google Scholar
• Humira (adalimumab) [package insert]. North Chicago IL: AbbVie Inc.; 2021.
   Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Cimzia (certolizumab pegol) [package insert]. Smyrna GA: UCB, Inc.; 2019.
   Google Scholar
• Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018 Aug 01;79(2):266–276.e5.
   PubMed Web of Science ®Google Scholar
• Cosentyx (secukinumab) [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2021.
   Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Taltz (ixekizumab) [package insert]. Indianapolis IN: Eli Lilly and Company; 2021.
   Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015 Aug 8 386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Siliq (brodalumab) [package insert]. Grand Duchy of Luxembourg, L-1931. Luxembourg: Valeant Pharmaceuticals Luxembourg S.à.r.l.; 2017.
   Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020 Jul;99(1):2–8.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018 Sep 15 201(6):1605–1613.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013 Apr;34(4):174–181.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov 01;13(5):715–725.
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699–5708.
   PubMed Web of Science ®Google Scholar
• Stelara (ustekinumab) [package insert]. Horsham PA: Janssen Biotech, Inc.; 2020.
   Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665–74.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 May 17;371(9625):1675–84.
   PubMed Web of Science ®Google Scholar
• Stelara (ustekinumab) European public assessment report (EPAR). European Medicines Agency; 2009 [cited 2020 Apr 6]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/stelara
   Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015 Oct;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020 Oct;183(4):664–672.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535–1545.
   PubMed Web of Science ®Google Scholar
• Langley R, Lebwohl M, Krueger G, et al. Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up. Br J Dermatol. 2015;172(5):1371–1383.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015 Jul;14(7):706–714.
   PubMed Web of Science ®Google Scholar
• Tremfya (guselkumab) [package insert]. Horsham PA: Janssen Biotech, Inc.; 2020.
   Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017 Mar;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Tremfya (guselkumab) European public assessment report (EPAR). European Medicines Agency; 2017 [cited 2022 Mar 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya
   Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019 Sep 7;394(10201):831–839.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018 Jan;178(1):114–123.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022 May;162(6):1650–1664.e8.
   PubMed Web of Science ®Google Scholar
• A study of guselkumab subcutaneous therapy in participants with moderately to severely active crohn’s disease (GRAVITI). U.S. National Institutes of Health; 2022 [cited 2022 Jun 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT05197049
   Google Scholar
• Mohanakrishnan R, Beier S, Deodhar A. IL-23 inhibition for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2022 Jan 02;22(1):59–65.
   PubMed Web of Science ®Google Scholar
• Guselkumab in the treatment of pityriasis rubra pilaris (PRP). U.S. National Institutes of Health; 2019 [cited 2022 Apr 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03975153
   Google Scholar
• Guselkumab for hidradenitis suppurativa, a mode of action study (HiGUS). U.S. National Institutes of Health; 2019 [cited 2019 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04061395
   Google Scholar
• A study of guselkumab in participants with familial adenomatous polyposis. U.S. National Institutes of Health; 2018 [cited 2022 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03649971
   Google Scholar
• A study to evaluate guselkumab for the treatment of participants with new-onset or relapsing giant cell arteritis (THEIA). U.S. National Institutes of Health; 2020 [cited 2022 Sep 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04633447
   Google Scholar
• A study of guselkumab therapy in participants with moderately to severely active ulcerative colitis (ASTRO). U.S. National Institutes of Health; 2022 [cited 2022 Sept 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT05528510
   Google Scholar
• A study of guselkumab in participants with systemic sclerosis. U.S. National Institutes of Health; 2020 [cited 2022 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT04683029
   Google Scholar
• An efficacy and safety study of CNTO1959 (Guselkumab) in the treatment of participants with generalized pustular psoriasis or erythrodermic Psoriasis. U.S. National Institutes of Health; 2015 [cited 2019 Oct 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT02343744
   Google Scholar
• A study of guselkumab in participants with active lupus nephritis (ORCHID-LN). U.S. National Institutes of Health; 2020 [cited 2022 Sep 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04376827
   Google Scholar
• Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease. U.S. National Institutes of Health; 2021 [cited 2021 May 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT04736966
   Google Scholar
• A study to evaluate the efficacy, safety, and pharmacokinetics of subcutaneously administered guselkumab for the treatment of chronic plaque psoriasis in pediatric participants (PROTOSTAR). U.S. National Institutes of Health; 2018 [cited 2022 Sep 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT03451851
   Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 Phase 3 study. Am J Clin Dermatol. 2020 Dec;21(6):881–890.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022 Apr;86(4):827–834.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017 Jul 15;390(10091):276–288.
   PubMed Web of Science ®Google Scholar
• Ilumya (tildrakizumab-asmn) [package insert]. Whitehouse Station NJ: Merck & Co., Inc.; 2018.
   Google Scholar
• Ilumetri (tildrakizumab) European public assessment report (EPAR). European Medicines Agency; 2018 [cited 2022 May 13]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri
   Google Scholar
• Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 Sep;80(9):1147–1157.
   PubMed Web of Science ®Google Scholar
• The effects of tildrakizumab in treatment of bullous pemphigoid. U.S. National Institutes of Health; 2020 [cited 2020 Jul 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT04465292
   Google Scholar
• Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo (TILDVIT-1227). U.S. National Institutes of Health; 2021 [cited 2022 Apr 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04971200
   Google Scholar
• Tildrakizumab for prevention of acute graft-versus-host disease. U.S. National Institutes of Health; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04112810
   Google Scholar
• Efficacy and Safety Study of SUNPG1622. U.S. National Institutes of Health; 2016 [cited 2021 Nov 1]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02980705
   Google Scholar
• A study of tildrakizumab in pediatric subjects with chronic plaque psoriasis. U.S. National Institutes of Health; 2019 [cited 2022 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03997786
   Google Scholar
• Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021 Aug;185(2):323–334.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018 Sep;179(3):615–622.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren R, Iversen L, et al. Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–617.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 Aug 25;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Soliman AM, Yang H, et al. Impact of risankizumab on PASI90 and DLQI0/1 duration in moderate-to-severe psoriasis: a post Hoc analysis of four phase 3 clinical trials. Dermatol Ther (Heidelb). 2022 Feb;12(2):407–418.
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019 Aug 17;394(10198):576–586.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658.
   PubMed Web of Science ®Google Scholar
• Skyrizi (risankizumab-rzaa) [package insert]. North Chicago IL: AbbVie Inc.; 2022.
   Google Scholar
• Skyrizi (risankizumab) European public assessment report (EPAR). European Medicines Agency; 2019 [cited 2022 Apr 1]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi
   Google Scholar
• A study of subcutaneous risankizumab injection for pediatric participants with moderate to severe plaque psoriasis to assess change in disease Symptoms. U.S. National Institutes of Health; 2020 [cited 2022 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04435600?
   Google Scholar
• Brightling CE, Nair P, Cousins DJ, et al. Risankizumab in severe asthma - a phase 2a, placebo-controlled trial. N Engl J Med. 2021 Oct 28 385(18):1669–1679.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panés J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671–680.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022 Feb;81(2):225–231.
   PubMed Web of Science ®Google Scholar
• A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa (DETERMINED 1). U.S. National Institutes of Health; 2018 [cited 2022 Jan 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03926169
   Google Scholar
• Multicenter A, Randomized D-B, Placebo controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis. U.S. National Institutes of Health; 2018 [cited 2022 Jun 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03398148
   Google Scholar
• Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019 Aug;46(8):686–694.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Pinter A, Ferris LK, et al. Long-term, durable, absolute psoriasis area and severity index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2022 Jun;36(6):855–865.
   PubMed Web of Science ®Google Scholar
• Papp KA, Lebwohl MG, Puig L, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021 Dec;185(6):1135–1145.
   PubMed Web of Science ®Google Scholar
• Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021 Dec;185(6):1146–1159.
   PubMed Web of Science ®Google Scholar
• A study to assess the efficacy of risankizumab compared to FUMADERM® in subjects with moderate to severe plaque psoriasis who are naïve to and candidates for systemic therapy. U.S. National Institutes of Health; 2017 [cited 2019 Sep 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03255382
   Google Scholar
• Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020 Mar;182(3):605–617.
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013 Apr;168(4):844–854.
   PubMed Web of Science ®Google Scholar
• Bimzelx (bimekizumab) Eurpoean public assessment report (EPAR). European Medicines Agency; 2021 [cited 2022 May 17]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx
   Google Scholar
• A study of mirikizumab (LY3074828) in participants with active Crohn’s disease (SERENITY). U.S. National Institutes of Health; 2016 [cited 2022 Feb 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02891226
   Google Scholar
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1). U.S. National Institutes of Health; 2018 [cited 2022 Feb 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03518086
   Google Scholar
• Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295–1302.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019 Feb;71(2):258–270.
   PubMed Web of Science ®Google Scholar
• Yu RY, Gallagher G. A naturally occurring, soluble antagonist of human IL-23 inhibits the development and in vitro function of human Th17 cells. J Immunol. 2010 Dec 15; 185(12):7302–7308.
   PubMed Web of Science ®Google Scholar
• Guo W, Luo C, Wang C, et al. Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region. PLoS One. 2012;7(9):e45625.
   PubMed Web of Science ®Google Scholar
• Gao Y, Bian Z, Xue W, et al. Human IL-23R cytokine-binding homology region-Fc fusion protein ameliorates psoriasis via the decrease of systemic Th17 and ILC3 cell responses. Int J Mol Sci. 2019 Aug 26;20(17). 10.3390/ijms20174170.
   Web of Science ®Google Scholar
• Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973–8995.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Strober B, Gordon KB, et al. Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial. Dermatol Ther. 2022;12(2):495–510.
   PubMed Web of Science ®Google Scholar
• Warren RB, Armstrong A, Gooderham M, et al., editors. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. 30th EADV Congress; 2021; Lugano, Switzerland: European Academy of Dermatology and Venereology.
   Google Scholar
• Effectiveness and safety of BMS-986165 compared to placebo and active comparator in participants with psoriasis (POETYK-PSO-1). U.S. National Institutes of Health; 2018 [cited 2021 Sept 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03624127
   Google Scholar
• An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis (POETYK-PSO-2): U.S. National Institutes of Health; 2018 [cited 2021 Dec 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03611751
   Google Scholar
• Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313–1321.
   PubMed Web of Science ®Google Scholar
• Thaçi, D. P1407 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared with Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials, 30th EADV Congress, September 29, 2021; 2021; Lugano, Switzerland: European Academy of Dermatology and Venereology.
   Google Scholar
• Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6): 815–822.
   PubMed Web of Science ®Google Scholar